
AAV Vectors In Gene Therapy Clinical Trials
Adeno-associated virus (AAV) vectors have become a leading delivery platform in gene therapy due to their improved safety profile and tissue specificity. Since the FDA’s 2017 approval of Luxturna, AAV has been widely adopted for gene replacement therapies, …